NSAM
CRSP icon

North Star Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

North Star Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$247K Hold
4,525
– – 0.01% 330
2026
Q1 		$215K Hold
4,525
– – 0.01% 330
2025
Q4 		$237K Hold
4,525
– – 0.01% 312
2025
Q3 		$293K Buy
4,525
+20
+0.4% +$1.15K 0.01% 287
2025
Q2 		$219K Buy
+4,505
New +$174K 0.01% 314

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

North Star Asset Management's CRSP Position: Q2 2026 in Review

North Star Asset Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 4,525 shares worth $247K. The position accounts for 0.01% of the portfolio, ranked #330.

North Star Asset Management first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. The position peaked at $293K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • North Star Asset Management held 4,525 shares of CRISPR Therapeutics worth $247K as of Q2 2026.
  • North Star Asset Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 0.01% of North Star Asset Management's portfolio in Q2 2026, its #330 holding.
  • North Star Asset Management first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • North Star Asset Management's CRISPR Therapeutics position peaked at $293K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on North Star Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.